At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 8 enrolled
Drug / intervention
14C-OPS-2071drug
Likely dose
14C-OPS-2071 25 mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1,Open -Label Study to Assess the Absorption, Metabolism and Excretion of 14C-OPS-2071 Following a Single Oral Dose to Healthy Male Japanese Subjects
In Brief
A Phase 1 clinical trial evaluating 14C-OPS-2071 for Bacterial Enteritis. Completed, enrolled 8 participants across 1 site.
Detailed Summary
To obtain absorption, metabolism and excretion data for parent drug and any metabolites.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBacterial Enteritis
CountriesUnited Kingdom
Collaborators--
Timeline
Phase 1CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartMay 2015
First PostedMay 2015
Primary CompletionAug 2015
TodayJul 2026
First PostedMay 12, 2015
Enrollment StartMay 1, 2015
Primary CompletionAug 1, 2015
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 11.1 years ago
Interventions
14C-OPS-2071drug
Subjects will swallow Single 25 mL of suspension containing 50 mg of 14C-OPS-2071 directly.